Terms: = Skin cancer AND APOBEC3B, ARP4, 9582, ENSG00000179750, DJ742C19_2, _phorbolin 3_, PHRBNL, FLJ21201, Q9UH17, bK150C2_2, APOBEC1L, ARCD3 AND Treatment
22017 results:
1. Observation of lymphadenopathy, systemic symptoms, and treatment in suspected indolent cutaneous B-cell lymphomas.
Puccio J; Huang Y; Viveiros MD; Reneau JC; Chung C; Spaccarelli N; Dulmage B
Arch Dermatol Res; 2024 May; 316(5):199. PubMed ID: 38775835
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of Acute Toxicities, Overall treatment Time and Quality of Life in Head and Neck cancer Patients Treated with IMRT and Helical Tomotherapy.
R YB; Swamy K; Swaroopa C; Maiya V
Gulf J Oncolog; 2024 May; 1(45):7-14. PubMed ID: 38774928
[TBL] [Abstract] [Full Text] [Related]
3. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases.
Hwang A; Kwon A; Miller CH; Reimer-Taschenbrecker A; Paller AS
Orphanet J Rare Dis; 2024 May; 19(1):206. PubMed ID: 38769503
[TBL] [Abstract] [Full Text] [Related]
4. Mortality trend of cutaneous melanoma in Montenegro from 1990-2018.
Nedovic Vukovic M; Terzic Z; Golubovic M; Bojic M; Bukumiric Z
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3463-3472. PubMed ID: 38766804
[TBL] [Abstract] [Full Text] [Related]
5. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
6. Subminute thermal damage to cell types present in the skin.
Doppegieter M; van Leeuwen TG; van Weert A; Aalders MCG; Bakker ENTP
Int J Hyperthermia; 2024; 41(1):2354435. PubMed ID: 38754976
[TBL] [Abstract] [Full Text] [Related]
7. Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy.
Mørk E; Mjønes P; Foss OA; Mørk C; Bachmann IM; Kroon S; Dotterud LK; Helsing P; Vatne Ø; Christensen E
Acta Derm Venereol; 2024 May; 104():adv18308. PubMed ID: 38751175
[TBL] [Abstract] [Full Text] [Related]
8. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
[TBL] [Abstract] [Full Text] [Related]
9. Prospective phase II trial of preoperative hypofractionated proton therapy for extremity and truncal soft tissue sarcoma: the PRONTO study rationale and design.
Gogineni E; Chen H; Hu C; Boudadi K; Engle J; Levine A; Deville C
Radiat Oncol; 2024 May; 19(1):56. PubMed ID: 38745333
[TBL] [Abstract] [Full Text] [Related]
10. Hospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17-year retrospective study.
Amonchaisakda N; Rujitharanawong C; Tuchinda P; Kulthanan K; Chularojanamontri L
Exp Dermatol; 2024 May; 33(5):e15095. PubMed ID: 38742822
[TBL] [Abstract] [Full Text] [Related]
11. [Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data].
Stoyukhina AS
Vestn Oftalmol; 2024; 140(2. Vyp. 2):16-20. PubMed ID: 38739126
[TBL] [Abstract] [Full Text] [Related]
12. A dosiomics model for prediction of radiation-induced acute skin toxicity in breast cancer patients: machine learning-based study for a closed bore linac.
Saadatmand P; Mahdavi SR; Nikoofar A; Jazaeri SZ; Ramandi FL; Esmaili G; Vejdani S
Eur J Med Res; 2024 May; 29(1):282. PubMed ID: 38735974
[TBL] [Abstract] [Full Text] [Related]
13. In Vitro and In Vivo Studies of Melanoma Cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM.
Pompili SVB; Fanzini S; Schachner M; Chen S
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732030
[TBL] [Abstract] [Full Text] [Related]
14. Glycyrrhizic acid inhibits DNA damage repair and enhances cisplatin-induced apoptosis of melanoma cells.
Bian F; Niu FH; Qu PY; Gong F; Yan JZ
Chem Biol Drug Des; 2024 May; 103(5):e14536. PubMed ID: 38725079
[TBL] [Abstract] [Full Text] [Related]
15. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.
Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA
Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373
[TBL] [Abstract] [Full Text] [Related]
16. Monitoring Adolescent and Young Adult Patients With cancer via a Smart T-Shirt: Prospective, Single-Cohort, Mixed Methods Feasibility Study (OncoSmartShirt Study).
Steen-Olsen EB; Pappot H; Hjerming M; Hanghoej S; Holländer-Mieritz C
JMIR Mhealth Uhealth; 2024 May; 12():e50620. PubMed ID: 38717366
[TBL] [Abstract] [Full Text] [Related]
17. The Application of "Table Tennis Racquet" Random skin Flap in the treatment of Facial skin Carcinoma.
Tian K; Jia Z; Xu W; Wang X; Xie X; Gu Y; Cao S; Gao S; Li K; Wu L
Ann Plast Surg; 2024 Jun; 92(6):647-652. PubMed ID: 38717142
[TBL] [Abstract] [Full Text] [Related]
18. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract] [Full Text] [Related]
19. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract] [Full Text] [Related]
20. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma skin cancers.
Ravipati A; Pradeep T; Nouri K
J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
[TBL] [Abstract] [Full Text] [Related]
[Next]